Epigenetic protein families: a new frontier for drug discovery
The DOI matches its Crossref record; 192 of the 194 references it cites were found in a registry or an index.
Abstract
Epigenetic regulation of gene expression is a dynamic and reversible process that establishes normal cellular phenotypes but also contributes to human diseases. At the molecular level, epigenetic regulation involves hierarchical covalent modification of DNA and the proteins that package DNA, such as histones. Here, we review the key protein families that mediate epigenetic signalling through the acetylation and methylation of histones, including histone deacetylases, protein methyltransferases, lysine demethylases, bromodomain-containing proteins and proteins that bind to methylated histones. These protein families are emerging as druggable classes of enzymes and druggable classes of protein-protein interaction domains. In this article, we discuss the known links with disease, basic molecular mechanisms of action and recent progress in the pharmacological modulation of each class of proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have also been demonstrated to possess greater isoform selectivity profiles, targeting specifically only the class I subgroup of HDACs (6-10, 26, 38, 39).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
In the citing paper
“The benzamides face a more difficult path to the observed binding mode, with two plausible binding trajectories. The ligand could enter via an acetyl release and disposal channel (7, 24, 33, 42) or via the hydrophobic tube, settling into a rearranged foot pocket before forming the zinc complex, which locks the inhibitor in place.”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [7]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
SMART, a simple modular architecture research tool: Identification of signaling domains
Schultz, J., Milpetz, F., Bork, P., & Ponting, C. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5857 · Cited by 3,599
Research works printed but not linked: 1
- Allis, C. D., Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Laboratory Press, New York, 2007).
Cited by
Items 201–300 of 1,001
Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4
Lamaa, D., Lin, H., Zig, L., Bauvais, C., Bollot, G., Bignon, J. S., Levaïque, H., Pamlard, O., Dubois, J., Ouaïssi, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00050 · Cited by 89
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia
Arteaga, M. F., Mikesch, J.-H., Qiu, J., Christensen, J., Helin, K., Kogan, S. C., Dong, S., & So, C. W. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.014 · Cited by 88
“This has also led to a recent burst of international efforts in developing specific inhibitors toward these enzymes (Arrowsmith et al., 2012).”
BackgroundSpiliotopoulos, D., Spitaleri, A., & Musco, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046902 · Cited by 89
“PHD fingers are indeed emerging as druggable classes of protein-protein interaction domains and they represent a new frontier in drug discovery that has a huge potential for the development of future therapeutics [42].”
BackgroundTian, X., Zhang, S., Liu, H., Zhang, Y., Blair, C., Mercola, D., Sassone‐Corsi, P., & Zi, X. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313050007 · Cited by 100
“So far, there are more than 50 human KMTs and 30 KDMs that have been identified [19, 20].”
The Functional Analysis of Histone Acetyltransferase MOF in Tumorigenesis
Su, J., Wang, F., Cai, Y., & Jin, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010099 · Cited by 95
A Structural Perspective on Readout of Epigenetic Histone and DNA Methylation Marks
Patel, D. J. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018754 · Cited by 87
Xue, X., Zhang, Y., Liu, Z., Song, M., Xing, Y., Xiang, Q., Wang, Z., Tu, Z., Zhou, Y., Ding, K., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01511 · Cited by 87
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
Zahnow, C. A., Topper, M. J., Stone, M. L., Stewart, T. M., Li, H., Baylin, S. B., & Casero, R. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.007 · Cited by 95
Epigenetic drug discovery for Alzheimer’s disease
Cacabelos, R., & Torrellas, C. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.930124 · Cited by 96
“2 EVP-0334 EVP-0334 is a CNS-penetrant HDAC (class I) inhibitor and has been developed and studied in a Phase I clinical trial for the treatment of AD [124].”
MethodEpigenetic targets for novel therapies of lung diseases
Comer, B. S., Ba, M. A., Singer, C. A., & Gerthoffer, W. T. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.006 · Cited by 92
“Bromodomain-containing proteins of the histone code “reader”machinery bind acetylated lysine residues on histones and function as transcriptional coactivators (Arrowsmith et al., 2012; Zhang et al., 2012b).”
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
Sonnemann, J., Marx, C., Becker, S., Wittig, S., Palani, C. D., Krämer, O. H., & Beck, J. F. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.742 · Cited by 92
“Histone deacetylase inhibitors block, with distinct specificities, a subset of the 18 isozymes belonging to the HDAC superfamily (Arrowsmith et al, 2012; Spiegel et al, 2012).”
Chemical basis for the recognition of trimethyllysine by epigenetic reader proteins
Kamps, J. J. A. G., Huang, J., Poater, J., Xu, C., Pieters, B. J. G. E., Dong, A., Min, J., Sherman, W., Beuming, T., Bickelhaupt, F. M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9911 · Cited by 87
“In comparison with the advances in development of inhibitors of other epigenetic targets, including bromodomains and various eraser/writer enzymes, there has been very limited success in identification of probes for readers of Kme3 (refs 54,55).”
Zhang, X., Kong, Y., Zhang, J., Su, M., Zhou, Y., Zang, Y., Li, J. X., Chen, Y., Fang, Y., Zhang, X., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.035 · Cited by 89
Gale, M., Sayegh, J., Cao, J. P., Norcia, M., Gareiss, P. C., Hoyer, D., Merkel, J. S., & Yan, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.9539 · Cited by 88
“Deregulation of epigenetic regulators is associated with many human diseases including inflammatory disorders, metabolic disorders, neurological disorders, and cancer [3].”
BackgroundProtein Methyltransferases: A Distinct, Diverse, and Dynamic Family of Enzymes
Boriack‐Sjodin, P. A., & Swinger, K. K. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b01129 · Cited by 95
AdoMet analog synthesis and utilization: current state of the art
Huber, T. D., Johnson, B. R., Zhang, J., & Thorson, J. S. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.07.005 · Cited by 84
Privileged Diazepine Compounds and Their Emergence as Bromodomain Inhibitors
Smith, S. G., Sanchez, R., & Zhou, M.-M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.03.004 · Cited by 81
“Inhibitors of bromodomain-containing proteins are a part of the extensive pipeline of epigenetic modulators that has the potential to bring advanced, targeted treatments to patients in the near future (Arrowsmith et al., 2012; Dawson et al., 2012; DeWoskin and Million, 2013; Kelly et al., 2010).”
BackgroundInduction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
Borbély, G., Haldosén, L.-A., Dahlman‐Wright, K., & Zhao, C. (2015) · Oncotarget · doi:10.18632/oncotarget.5601 · Cited by 83
“Histone acetylation also directly promotes transcription by providing binding sites for BET proteins that recognize or “read” histone modifications and assemble a complex of co-regulatory proteins such as positive transcription elongation factor b complex (P-TEFb) to facilitate gene transcription [6, 7].”
Metabolic regulation of tissue stem cells
Shapira, S. N., & Christofk, H. R. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.04.004 · Cited by 82
Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J. S., Gunatilake, D., Madore, J., Strbenac, D., Yang, J. Y., Gowrishankar, K., Tiffen, J. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4242 · Cited by 82
Malaria EpigeneticsPreprint
Cortés, A., & Deitsch, K. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025528 · Cited by 85
“…inhibitors of this type of enzymes have been developed for the fight against other diseases such as cancer, providing a large number of chemical starting points and a wealth of knowledge that could be used for the development of malaria-specific epigenetic inhibitors (Arrowsmith et al. 2012).”
BackgroundPathological conditions re-shape physiological Tregs into pathological Tregs
Yang, W. Y., Shao, Y., Lopez‐Pastrana, J., Mai, J., Wang, H., & Yang, X. (2015) · Burns & Trauma · doi:10.1186/s41038-015-0001-0 · Cited by 85
“So far, epigenetic modifications have been grouped into four main categories: DNA methylation, histone modification including histone methylation/demethylation, histone acetylation/deacetylation, histone phosphorylation, histone SUMOylation [124], small and long noncoding RNAs, as well as chromatin remodeling [124,125…”
BackgroundDaze, K. D., Pinter, T., Beshara, C. S., Ibraheem, A., Minaker, S. A., Manuel, C. F., Courtemanche, R. J. M., Campbell, R. E., & Hof, F. A. (2012) · Chemical Science · doi:10.1039/c2sc20583a · Cited by 82
Du, W., Wang, N., Li, F., Jia, K., An, J., Liu, Y., Wang, Y., Zhu, L., Song, Z., & Hao, J. (2019) · The FASEB Journal · doi:10.1096/fj.201900127r · Cited by 86
“So far, there are 18 HDAC family members identified, which are grouped into 4 classes: class I (HDAC1, 2, 3, and8), class II (HDAC4, 5, 6, 7, 9, and 10), class III (sirtuin 1, 2, 3, 4, 5, 6, and 7), and class IV (HDAC11) (17).”
BackgroundOsko, J. D., & Christianson, D. W. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00934 · Cited by 77
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Montalvo-Casimiro, M., González‐Barrios, R., Meraz-Rodríguez, M. A., Juárez-González, V. T., Arriaga-Canon, C., & Herrera, L. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605386 · Cited by 88
Chromatin plasticity predetermines neuronal eligibility for memory trace formation
Santoni, G., Astori, S., Leleu, M., Glauser, L., Zamora, S. A., Schioppa, M., Tarulli, I., Sandi, C., & Gräff, J. (2024) · Science · doi:10.1126/science.adg9982 · Cited by 82
“To experimentally increase H3K27ac, we overexpressed two members of the phylogenetically opposite poles of the HAT family, CREB-binding protein (CBP) and Lysine acetyltransferase 5 (KAT5) ( 21 ) (Fig.”
Epigenetic regulation in lung cancer
Ramazi, S., Dadzadi, M., Sahafnejad, Z., & Allahverdi, A. (2023) · MedComm · doi:10.1002/mco2.401 · Cited by 97
Chan, A., & Chen, C.-W. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00081 · Cited by 95
Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors
Liu, F., Li, F., Ma, A., Dobrovetsky, E., Dong, A., Gao, C., Korboukh, I., Liu, J., Smil, D. V., Brown, P. J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3018332 · Cited by 84
“1-(Benzo[d][1,2,3]thiadiazol-6-yl)-3-(2-(piperidin-1-yl)ethyl)-urea (14b)—The procedure used for preparation of compound 4 was followed for synthesis of 14b.”
BackgroundMethodInfluentialSelf-citationKlotho: a novel biomarker for cancer
Zhou, X., & Wang, X. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1788-y · Cited by 82
“Epigenetic silencing of Klotho in cancers Epigenetic regulation is a dynamic process that contributes to many human chronic diseases, such as cancer, inflammation, and diabetes (Arrowsmith et al. 2012).”
BackgroundEpigenetic mechanisms of neurodegenerative diseases and acute brain injury
Bertogliat, M. J., Morris-Blanco, K. C., & Vemuganti, R. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104642 · Cited by 87
The discovery of colchicine-SAHA hybrids as a new class of antitumor agents
Zhang, X., Zhang, J., Tong, L., Luo, Y., Su, M., Zang, Y., Li, J. X., Lu, W. P., & Chen, Y. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.049 · Cited by 82
KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases
Simon, R. P., Robaa, D., Alhalabi, Z., Sippl, W., & Jung, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01502 · Cited by 74
Niederberger, E., Resch, E., Parnham, M. J., & Geißlinger, G. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.68 · Cited by 83
Clinical progress and pharmacology of small molecule bromodomain inhibitors
Theodoulou, N. H., Tomkinson, N. C. O., Prinjha, R. K., & Humphreys, P. G. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.05.028 · Cited by 76
“3 This disclosure and ready availability of high quality small molecules such as I-BET762 (1) and (+)-JQ1 (2) stimulated academic and industrial research in the field.”
BackgroundInfluentialA Chemical Proteomics Approach for Global Analysis of Lysine Monomethylome Profiling *
Wu, Z., Cheng, Z., Sun, M., Wan, X., Liu, P., Tie-ming, H., Tan, M., & Zhao, Y. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044255 · Cited by 85
“a group of promising drug targets (7, 10, 11).”
BackgroundIdentification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Clermont, P., Crea, F., Chiang, Y. T., Lin, D., Zhang, A. X. W., Wang, J. Z. L., Parolia, A., Wu, R. C., Xue, H., Wang, Y., et al. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0182-9 · Cited by 79
Paolella, B. R., Gibson, W. J., Urbanski, L. M., Alberta, J. A., Zack, T. I., Bandopadhayay, P., Nichols, C. A., Agarwalla, P. K., Brown, M. S., Lamothe, R. C., et al. (2017) · eLife · doi:10.7554/elife.23268 · Cited by 86
“Another approach may be to reduce levels of protein encoded by CYCLOPS genes, either by interfering with the transcription of these genes (Arrowsmith et al., 2012; Kwiatkowski et al., 2014) or by enhancing protein degradation (Bondeson et al., 2015; D’Arcy et al., 2015; Winter et al., 2015).”
BackgroundHuang, Y., Yu, S., Zhen, W., Cheng, T., Wang, D., Lin, J., Wu, Y., Wang, Y., Chen, Y., Shu, L., et al. (2021) · Theranostics · doi:10.7150/thno.53170 · Cited by 76
“The specificity, reversibility, and dynamics of these controls make them ideal drug targets [1].”
BackgroundJumonji histone demethylases as emerging therapeutic targets
Park, S. Y., Park, J., & Chun, Y. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.026 · Cited by 83
Urick, A. K., Hawk, L. M. L., Cassel, M. K., Mishra, N. K., Liu, S., Adhikari, N., Zhang, W., dos Santos, C. O., Hall, J. L., & Pomerantz, W. C. K. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00483 · Cited by 74
Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study
Wan, S., Bhati, A. P., Zasada, S. J., Wall, I. D., Green, D. V. S., Bamborough, P., & Coveney, P. V. (2016) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b00794 · Cited by 85
Gao, Y., Zhang, H., Lirussi, F., Garrido, C., Ye, X., & Xie, T. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114224 · Cited by 73
Targeting Histone Methylation in Cancer
McCabe, M. T., Mohammad, H. P., Barbash, O., & Kruger, R. G. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000283 · Cited by 79
“DOT1L contains a unique methyltransferase domain that clusters with the PRMTs based on structural and sequence similarity.(29) Regardless of their catalytic domain, all KMTs function by aligning the s-adenosylmethionine (SAM)methyl donor with the lysine methyl acceptor and promoting transfer of a methyl group from SAM…”
BackgroundComputer-Aided Drug Design in Epigenetics
Lu, W., Zhang, R., Jiang, H., Zhang, H., & Luo, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00057 · Cited by 81
“Based on their different substrates and their relative functions, erasers could be divided into different families such as histone deacetylases (HDACs), RNA demethyltransferases, histone demethylases (HDMs), histone deubiquitinases, and so on (Arrowsmith et al., 2012).”
BackgroundInnovative Strategies for Selective Inhibition of Histone Deacetylases
Maolanon, A. R., Madsen, A. S., & Olsen, C. A. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.011 · Cited by 72
Zhang, Q., Chen, Y., Ni, D., Huang, Z., Wei, J., Li, F., Su, J., Wei, Y., Ning, S., Yang, X., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.015 · Cited by 74
Williams, D. E., Dalisay, D. S., Li, F., Amphlett, J. T. M., Maneerat, W., Chavez, M. A. G., Wang, Y. A., Matainaho, T. K., Yu, W., Brown, P. J., et al. (2012) · Organic Letters · doi:10.1021/ol303416k · Cited by 72
Self-citationWestaway, S. M., Preston, A. G. S., Barker, M. D., Brown, F., Brown, J. A., Campbell, M. J., Chung, C., Drewes, G., Eagle, R., Garton, N. S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01538 · Cited by 72
Self-citationThe Role of the Double Bromodomain-Containing BET Genes During Mammalian Spermatogenesis
Berkovits, B. D., & Wolgemuth, D. J. (2012) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416024-8.00011-8 · Cited by 82
Pike, J. W., Lee, S. M., & Meyer, M. B. (2014) · BoneKEy Reports · doi:10.1038/bonekey.2013.216 · Cited by 79
“These dynamic regulatory marks are imposed upon the genome by a diverse set of chromatin regulatory factors.(73) This epigenetic histone code for repeating features of the genome was identified and is supported by studies conducted through the ENCODE Consortium as well as other investigative groups.”
BackgroundNovel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
Liang, D., Yu, Y., & Ma, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112426 · Cited by 73
Peng, X., Chen, J., Li, L., Sun, Z., Liu, J., Ren, Y., Huang, J., & Chen, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00413 · Cited by 74
Shrimp, J. H., Sorum, A. W., Garlick, J. M., Guasch, L., Nicklaus, M. C., & Meier, J. L. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00385 · Cited by 70
Role of 5-hydroxymethylcytosine in neurodegeneration
Sherwani, S. I., & Khan, H. A. (2015) · Gene · doi:10.1016/j.gene.2015.06.052 · Cited by 75
“Research on small molecular diagnostic and therapeutic targets is underway, to modulate the epigenome and its function leading to better understanding and treatment options for various neurodegenerative diseases in the future (Arrowsmith et al., 2012; Bader Lange et al., 2010).”
BackgroundTargeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
Copeland, R. A., Moyer, M. P., & Richon, V. M. (2012) · Oncogene · doi:10.1038/onc.2012.552 · Cited by 75
Epigenomic regulation of host–microbiota interactions
Alenghat, T., & Artis, D. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.09.007 · Cited by 70
Carneiro, V. C., da Silva, I. C. D. A., Torres, E. J. L., Caby, S., Lancelot, J., Vanderstraete, M., Furdas, S. D., Jung, M., Pierce, R. J., & Fantappíé, M. R. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004116 · Cited by 70
“Epigenetic targets, including enzymes that introduce histone modifications affecting gene transcription, are particularly attractive because these enzymes are already targeted in a variety of pathologies, particularly cancer [23] and a large number of drug candidates have been developed that can serve as the basis for…”
BackgroundGruhn, B., Naumann, T., Gruner, D., Walther, M., Wittig, S., Becker, S., Beck, J. F., & Sonnemann, J. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.016 · Cited by 81
“016 received approval by the US Food and Drug Administration as second-line treatments for cutaneous T cell lymphoma [6].”
BackgroundPeng, X., Li, L., Chen, J., Ren, Y., Liu, J., Yu, Z., Cao, H., & Chen, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01863 · Cited by 70
PBRM1, SETD2 and BAP1 — the trinity of 3p in clear cell renal cell carcinoma
Walton, J., Lawson, K. A., Prinos, P., Finelli, A., Arrowsmith, C. H., & Ailles, L. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00659-1 · Cited by 82
Self-citationTowards understanding methyllysine readout
Musselman, C. A., Khorasanizadeh, S., & Kutateladze, T. G. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.04.001 · Cited by 81
Jia, W., Wu, W., Yang, D., Xiao, C., Su, Z., Huang, Z., Li, Z., Qin, M., Huang, M., Liu, S., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201701483r · Cited by 71
“Epigenetic mechanisms recently raised great interest in the study of the pathogenesis of chronic diseases (31, 32), with therapies targeting epigeneticmarks applied in several diseases ormodels (33, 34).”
BackgroundTeijido, Ó., & Cacabelos, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103199 · Cited by 71
“Among this group, one of the most promising epidrugs is the Forum Pharmaceutical compound (FRM-0334), specifically tested for dementia, which inhibits a subset of class I and II human HDACs with a high efficiency (nanomolar IC50 values) and addresses the issue of crossing the blood–brain barrier [189].”
BackgroundHu, Z., Zhou, J., Jiang, J., Yuan, J., Zhang, Y., Wei, X., Loo, N., Wang, Y., Pan, Y., Zhang, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08554-x · Cited by 73
“To predict the putative cancer-causing HAMP genes driven by mutation, five independent methods were integrated and applied to identify recurrent mutations: (1) MutSigCV (http://software.”
BackgroundMethodResultInfluentialSelectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors
Gryder, B. E., Akbashev, M. J., Rood, M. K., Raftery, E. D., Meyers, W. M., Dillard, P., Khan, S. A., & Oyelere, A. K. (2013) · ACS Chemical Biology · doi:10.1021/cb400542w · Cited by 73
“We were encouraged to find that every conjugate in the aryl series (14a–f) showed greater affinity than cyanonilutamide (1), bicalutamide (3) and enzalutamide.”
BackgroundMehta, S., Cronkite, D. A., Basavappa, M. G., Saunders, T. L., Adiliaghdam, F., Amatullah, H., Morrison, S. A., Pagan, J. D., Anthony, R. M., Tonnerre, P., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aag3160 · Cited by 72
Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain
Unzue, A., Xu, M., Dong, J., Wiedmer, L., Spiliotopoulos, D., Caflisch, A., & Nevado, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00172 · Cited by 66
Montgomery, D. C., Sorum, A. W., & Meier, J. L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502372j · Cited by 69
Wang, L., Pratt, J. K., Soltwedel, T., Sheppard, G. S., Fidanze, S. D., Liu, D., Hasvold, L. A., Mantei, R. A., Holms, J. H., McClellan, W. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00017 · Cited by 67
Microbiota-sensitive epigenetic signature predicts inflammation in Crohn’s disease
Kelly, D., Kotliar, M., Woo, V., Jagannathan, S., Whitt, J., Moncivaiz, J. D., Aronow, B. J., Dubinsky, M. C., Hyams, J. S., Markowitz, J. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122104 · Cited by 76
“Epigenetic modifications can regulate gene expression in response to environmental cues, without altering the genetic sequence (31).”
BackgroundMunteanu, B., Meyer, B., von Reitzenstein, C., Burgermeister, E., Bog, S., Pahl, A., Ebert, M. P., & Hopf, C. (2014) · Analytical Chemistry · doi:10.1021/ac500038j · Cited by 66
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
Epigenetic Control of Cytokine Gene Expression
Falvo, J. V., Jasenosky, L. D., Kruidenier, L., & Goldfeld, A. E. (2013) · Advances in immunology · doi:10.1016/b978-0-12-407708-9.00002-9 · Cited by 77
“Notably, BRD4 is a regulatory cofactor of the oncoprotein Myc, which has proven to be refractory to direct inhibition by therapeutic compounds (Arrowsmith et al., 2012).”
BackgroundMethodInfluentialEpigenetics in lung fibrosis: from pathobiology to treatment perspective
Helling, B. A., & Yang, I. V. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000191 · Cited by 70
“Similarly, histone methyltransferases add the methyl groups to histone tails, whereas histone demethylases remove them [55,56].”
BackgroundDo, C., Xing, Z., Yu, Y. E., & Tycko, B. (2017) · Epigenomics · doi:10.2217/epi-2016-0138 · Cited by 66
Chen, X., Wang, F., Zhang, Y., Ma, X., Cao, P., Yuan, L., Wang, L., Chen, J., Zhou, X., Wu, Q., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00504-5 · Cited by 74
“Inhibitors of DNA methylation and histone deacetylase (HDAC) inhibitors have been approved for clinical use in hematological malignancies, thus providing proof of concept for epigenetic therapies [23, 24].”
BackgroundEpigenetic regulation and T-cell responses in endometriosis – something other than autoimmunity
Szukiewicz, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943839 · Cited by 67
Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350,000 Compounds
Baell, J. B. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300461a · Cited by 69
Transgenerational inheritance of metabolic disease
Stegemann, R., & Buchner, D. A. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.04.007 · Cited by 59
“A number of compounds targeting the epigenome are already FDA approved or are in various stages of clinical trials, primarily for the treatment of cancer [114].”
BackgroundYao, Y., Tu, Z., Liao, C., Wang, Z., Li, S., Yao, H., Li, Z., & Jiang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01044 · Cited by 65
Small-Molecule Targets in Immuno-Oncology
Dhanak, D., Edwards, J. P., Nguyen, A., & Tummino, P. J. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.019 · Cited by 67
“Introduction Clinical experience with immune system-targeted therapeutics in oncology is revolutionizing the treatment of an increasing number of cancers of diverse histology (Allison, 2015; Postow et al., 2015).”
BackgroundResultEntropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6
Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00367 · Cited by 64
Wu, M., Hayward, D., Kalin, J. H., Song, Y., Schwabe, J. W. R., & Cole, P. A. (2018) · eLife · doi:10.7554/elife.37231 · Cited by 66
“Recent efforts to develop small molecule inhibitors of HDAC1 and LSD1 individually and selectively targeted to the CoREST complex (Arrowsmith et al., 2012; Højfeldt et al., 2013; Kalin et al., 2018; Mohammad et al., 2015; Prusevich et al., 2014) appear to show promise as anti-cancer agents.”
BackgroundA patent review of BRD4 inhibitors (2013-2019)
Lu, T., Lu, W., & Luo, C. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1702645 · Cited by 67
Luís, A. S., Vieira‐Coimbra, M., Vieira, F. Q., Costa‐Pinheiro, P., Silva‐Santos, R., Dias, P. C., Antunes, L., Lobo, F., Oliveira, J., Gonçalves, C. S., et al. (2015) · Epigenetics · doi:10.1080/15592294.2015.1103578 · Cited by 63
The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors
Li, X., Qu, J., Teng, X.-Q., Zhuang, H.-H., Dai, Y.-H., Yang, Z. G., & Qu, Q. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78535 · Cited by 71
“Epigenetic modifications alter cellular plasticity, differentiation, and reprogramming without changing the primary DNA sequence or the genetic code of organisms [3].”
BackgroundPulya, S., Himaja, A., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00614 · Cited by 66
Small Molecule Control of Chromatin Remodeling
Finley, A., & Copeland, R. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.024 · Cited by 70
Westaway, S. M., Preston, A. G. S., Barker, M. D., Brown, F., Brown, J. A., Campbell, M. J., Chung, C., Diallo, H., Douault, C., Drewes, G., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01537 · Cited by 63
Self-citationvan Zundert, G. C. P., Hudson, B. M., de Oliveira, S. H. P., Keedy, D. A., Fonseca, R., Heliou, A., Suresh, P., Borrelli, K., Day, T., Fraser, J. S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01292 · Cited by 65
Chemical Probes of Histone Lysine Methyltransferases
Kanıskan, H. Ü., & Jin, J. J. (2014) · ACS Chemical Biology · doi:10.1021/cb500785t · Cited by 67
Gallagher, S. J., Mijatov, B., Gunatilake, D., Tiffen, J. C., Gowrishankar, K., Jin, L., Pupo, G. M., Cullinane, C. M., Prinjha, R. K., Smithers, N. N., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.243 · Cited by 65
“The writers and erasers establish what is referred to as a ‘‘histone code’’ that is ‘‘read’’ by a third family of proteins that recognize the histone code and act to focus large protein complexes to those sites (Arrowsmith et al., 2012; Dawson et al., 2012).”
BackgroundSmall-Molecule Ligands of Methyl-Lysine Binding Proteins: Optimization of Selectivity for L3MBTL3
James, L. I., Korboukh, V. K., Krichevsky, L., Baughman, B. M., Herold, J. M., Norris, J. L., Jin, J. J., Kireev, D., Janzen, W. P., Arrowsmith, C. H., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400919p · Cited by 68
“Kme methyl-lysine Kme2 dimethyl-lysine SAR structure activity relationships PTM post-translational modification MBT malignant brain tumor L3MBTL3 Lethal(3)malignant brain tumor-like protein 3 L3MBTL1 Lethal(3)malignant brain tumor-like protein 1 TR-FRET time resolved fluorescence resonance energy transfer H4K20me1-2 m…”
MethodSelf-citationPAK4 Methylation by SETD6 Promotes the Activation of the Wnt/β-Catenin Pathway
Vershinin, Z., Feldman, M., Chen, A., & Levy, D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.697292 · Cited by 63
“There are 50 members of this family, of which all but one contains a conserved SET domain that carries out the enzymatic activity (8).”
BackgroundZhang, Z., Hou, S., Chen, H., Ran, T., Jiang, F., Bian, Y., Zhang, D., Zhi, Y., Wang, L., Zhang, L., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.034 · Cited by 68
Yuan, Z., Sun, Q., Li, D., Miao, S., Chen, S., Song, L., Gao, C., Chen, Y., Tan, C., & Jiang, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.017 · Cited by 62
Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery
Chen, W., Dong, G., Wu, Y., Zhang, W., Miao, C., & Sheng, C. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00414 · Cited by 54
Therapeutic potential of targeting LSD1/ KDM1A in cancers
Zhang, X., Wang, X., Wu, T., Yin, W., Yan, J., Sun, Y., & Zhao, D. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105958 · Cited by 64
Metadata
- Authors
- Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M.
- Affiliations
- University of Toronto (CA)
- University of Oxford (GB)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Arrowsmith, Cheryl H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-04-13
- Volume
- 11
- Issue
- 5
- Pages
- 384-400
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2076333986
- Semantic Scholar
- fd3346db3efdf967ef263b7d902523d5edecb53e
- Cited by
- 1,327
- References
- 194
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 47 · 2023: 47 · 2022: 62 · 2021: 85 · 2020: 103 · 2019: 103 · 2018: 93 · 2017: 126 · 2016: 165 · 2015: 132 · 2014: 115 · 2013: 116 · 2012: 54
- FWCI
- 12.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Genome Canada
- Wellcome Trust (1097737)
- Ontario Genomics
- Ontario Genomics Institute
- Canadian Institutes of Health Research (1097737)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic regulation, histone acetylation, histone methylation, histone deacetylase, protein methyltransferases, lysine demethylase, bromodomain proteins, epigenetic drug targets, epigenetic drug discovery, cancer, inflammation, neuropsychiatric disorders
- MeSH terms
- Acetylation, Animals, Gene Expression Regulation, Histones, Humans, Methylation, Protein Binding, Proteins, Signal Transduction, Epigenesis, Genetic, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.